LXEO — Lexeo Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1907108 ·
Last close
$3.21
Market Cap
$263.37M
52W High
$10.99
52W Low
$2.98
ADV30
1,494,284
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -28,020,000 | -25,867,000 | 254,898,000 | 92,834,000 | 19,837,000 |
| Mar 2026 | 0 | — | -22,333,000 | -20,196,000 | 250,356,000 | 71,768,000 | 18,859,000 |
| Dec 2025 | 0 | — | -23,116,000 | -20,919,000 | 268,688,000 | 63,000,000 | 22,019,000 |
| Sep 2025 | 0 | — | -21,648,000 | -20,283,000 | 143,844,000 | 40,996,000 | 23,013,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-97,989,000
Investing CF
$-78,392,000
Financing CF
$219,236,000
CapEx
$-324,000
Dividends Paid
—
Buybacks
$-4,000
EPS Diluted TTM
$-1.45
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-400,330,000
Inventory
—
Receivables
—
ST Investments
$121,275,000
EBIT TTM
$-87,318,000
Pretax Income TTM
$-87,501,000
Interest Exp TTM
$183,000
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -109,257,000 | -99,961,000 | 268,688,000 | 22,019,000 | 246,669,000 | -98,561,000 |
| Dec 2024 | 0 | -105,766,000 | -98,333,000 | 146,942,000 | 30,100,000 | 116,842,000 | -81,151,000 |
| Dec 2023 | 0 | -68,513,000 | -66,394,000 | 139,807,000 | 26,272,000 | 113,535,000 | -59,496,000 |
| Dec 2022 | 654,000 | -60,509,000 | -59,277,000 | 97,076,000 | 210,030,000 | -112,954,000 | -54,560,000 |
TTM Snapshot
Revenues TTM
$7,050,000
NetIncome TTM
$-87,501,000
OpCashFlow TTM
—
Assets (Latest)
$250,356,000
Forward EPS
$-1.37
Max Pain — expiry 2026-10-16
max pain strike: $4.00 · spot: $3.28 · call oi: 677 · put oi: 428
Expected Move to 2026-10-16:
±$0.35
(10.67%) —
implied range
$2.93 –
$3.63
· ATM straddle on $4.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SABS | SAB Biotherapeutics, Inc. | $262.95M | $2.89 | — |
| IPSC | Century Therapeutics, Inc. | $264.37M | $1.46 | — |
| LCTX | Lineage Cell Therapeutics, Inc. | $260.49M | $1.03 | — |
| IKT | Inhibikase Therapeutics, Inc. | $266.51M | $1.91 | — |
| FATE | FATE THERAPEUTICS INC | $255.22M | $2.13 | — |
News headlines (Yahoo Finance, 1h cache)
Lexeo Therapeutics to Participate in the Chardan Healthcare Conference
2026-10-08 11:00 · Yahoo
Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)
2026-10-01 13:00 · Yahoo
Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia
2026-09-23 12:00 · Yahoo
Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
2026-09-23 11:00 · Yahoo
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September
2026-09-02 11:00 · Yahoo
Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights
2026-08-12 11:00 · Yahoo
What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple
2026-07-15 15:43 · Yahoo
Is Lexeo Therapeutics, Inc. (LXEO) Stock Still a Gene Therapy Opportunity After Analyst Valuation Update?
2026-07-02 20:06 · Yahoo
Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia
2026-06-17 20:01 · Yahoo
Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia
2026-06-15 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.